ACE-031

ACE-031 is a recombinant fusion protein consisting of the extracellular ligand-binding domain of human Activin Receptor Type IIA (ActRIIA) fused to the Fc region of human IgG1. It functions as a soluble "decoy receptor" that competitively binds and sequesters myostatin (GDF-8), activin A, and GDF-11 — all members of the TGF-β superfamily that normally act as negative regulators of skeletal muscle mass. By preventing these ligands from engaging their cognate cell-surface receptors, ACE-031 derepresses anabolic muscle growth signaling, promoting muscle hypertrophy through increased protein synthesis and reduced protein degradation. Myostatin signaling through ActRIIB on myoblasts activates SMAD2/3 transcription factors, which suppress MyoD and myogenin expression — key drivers of myogenic differentiation and hypertrophic growth. ACE-031 blocks this inhibitory cascade at the ligand level, upstream of receptor engagement. Preclinical studies in mouse models demonstrate that ACE-031 administration produces significant increases in muscle mass (30–60%) within weeks, with concurrent decreases in fat mass. Phase I/II clinical trials in healthy adults and boys with Duchenne muscular dystrophy (DMD) confirmed rapid and substantial increases in lean body mass and thigh muscle volume. Research applications include Duchenne and Becker muscular dystrophies, spinal muscular atrophy, age-related sarcopenia, cancer cachexia, and metabolic syndrome. The Fc fusion confers an extended half-life (approximately 10–14 days), enabling infrequent dosing in research settings. ACE-031 represents one of the most potent pharmacological approaches to myostatin/activin pathway inhibition currently under investigation.